GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Price-to-Funds-From-Operations

CureVac NV (WBO:CVAC) Price-to-Funds-From-Operations : (As of Apr. 28, 2025)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


CureVac NV Business Description

Industry
Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.